Danaher Co. (NYSE:DHR) Shares Bought by ProShare Advisors LLC

ProShare Advisors LLC grew its position in Danaher Co. (NYSE:DHR) by 7.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 96,531 shares of the conglomerate’s stock after purchasing an additional 7,091 shares during the quarter. ProShare Advisors LLC’s holdings in Danaher were worth $24,118,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Cape Investment Advisory Inc. purchased a new stake in Danaher in the fourth quarter valued at about $25,000. Tsfg LLC raised its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the first quarter worth $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE DHR opened at $273.19 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock has a 50-day moving average of $268.16 and a 200 day moving average of $257.32. The stock has a market capitalization of $202.35 billion, a price-to-earnings ratio of 46.30, a PEG ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 EPS. Sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DHR. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Bank of America lifted their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Robert W. Baird lifted their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, TD Cowen increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Insider Buying and Selling

In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.